Expanding Medication-Assisted Therapies in Central Asia for Opioid Use Disorder
This study is looking at how to improve and expand the use of opioid agonist therapies (OAT) in Central Asia, a region with a growing HIV epidemic linked to injection drug use. Researchers are testing a behavioral intervention called NIATx (Network for the Improvement of Addiction Treatment) to help scale up OAT in Kazakhstan, Kyrgyzstan, and Tajikistan. The goal is to see if this approach can increase the number of people receiving OAT over 36 months. You might be eligible if you are 18 or older, meet the criteria for opioid dependence, and are either new to OAT or have been on it for less than 90 days. The study's current status is unclear.
- Study design
- This is an interventional study with a planned enrollment of 900 participants. It is not specified if it is randomized, blinded, or what phase it is in.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary outcomes will be measured at 36 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Expanding Medication-Assisted Therapies in Central Asia
At a glance
Conditions
Where it's being run
4 sites across 4 statesStudy leadership
- Frederick L Altice, MD · PRINCIPAL_INVESTIGATOR · Yale University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Exclusion
What this trial measures
- OAT Census36 months
Absolute number of patients on OAT per country
- OAT Census per Oblast36 months
Absolute number of patients on OAT per oblast